Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 15/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 15/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 15/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | BRS3 | P32247 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13421846 | 1.00 | PIM1 (0.35) | PIM1PIM3PIM2KDM1ABRS3 | |
| SCHEMBL4127523 | 1.00 | PIM1 (0.35) | PIM1PIM3PIM2KDM1ABRS3 | |
| SCHEMBL16588145 | 1.00 | PIM1 (0.35) | PIM1PIM3PIM2KDM1ABRS3 | |
| SCHEMBL3223805 | 1.00 | PIM1 (0.35) | PIM1PIM3PIM2KDM1ABRS3 | |
| SCHEMBL2839933 | 1.00 | PIM1 (0.35) | PIM1PIM3PIM2KDM1ABRS3 | |
| SCHEMBL3223798 | 1.00 | PIM1 (0.35) | PIM1PIM3PIM2KDM1ABRS3 | |
| SCHEMBL15588999 | 0.90 | PIM1 (0.41) | PIM1PIM3PIM2 | |
| SCHEMBL15589067 | 0.90 | PIM1 (0.41) | PIM1PIM3PIM2 | |
| SCHEMBL15589000 | 0.90 | PIM1 (0.41) | PIM1PIM3PIM2 | |
| SCHEMBL15589065 | 0.90 | PIM1 (0.41) | PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935270-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | Novartis AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| US-20150150873-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| EP-2861585-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2015-04-22 | — | — | EP | disclosed |
| WO-2014099880-A1 | ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS | NOVARTIS AG (CH) | 2014-06-26 | — | — | WO | disclosed |
| WO-2013175388-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150873-A1 | NOVEL RING-SUBSTITUTED N-PYRIDINYL AMIDES AS KINASE INHIBITORS | PIM1, PIM2, MAP3K1 | PIM1 1/4885PIM3 4/4885PIM2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.